Edition:
India

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

54.07USD
16 Nov 2018
Change (% chg)

$0.80 (+1.50%)
Prev Close
$53.27
Open
$53.50
Day's High
$54.81
Day's Low
$53.44
Volume
2,706,251
Avg. Vol
1,771,376
52-wk High
$70.04
52-wk Low
$46.95

Chart for

About

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small... (more)

Overall

Beta: 1.19
Market Cap(Mil.): $106,283.60
Shares Outstanding(Mil.): 1,639.93
Dividend: 0.39
Yield (%): 2.41

Financials

  BMY.N Industry Sector
P/E (TTM): 23.62 31.23 33.59
EPS (TTM): 2.74 -- --
ROI: 18.60 15.57 15.05
ROE: 30.97 16.94 16.62

Stada, Angelini among final bidders for $1 billion Bristol-Myers' UPSA unit: sources

FRANKFURT/LONDON German drugmaker Stada and Italian healthcare company Angelini are the only industry players to be shortlisted to make final bids for Bristol-Myers Squibb's French over-the-counter drugs business, four sources close to the deal said.

09 Nov 2018

UPDATE 1-Stada, Angelini among final bidders for $1 bln Bristol-Myers' UPSA unit - sources

* Bristol Myers to focus on high-margin prescription drugs (Adds context, details on valuation)

09 Nov 2018

Stada, Angelini among final bidders for $1 bln Bristol-Myers' Upsa unit - sources

FRANKFURT/LONDON, Nov 8 German drugmaker Stada and Italian healthcare company Angelini are the only industry players to be shortlisted to make final bids for Bristol-Myers Squibb's French over-the-counter drugs business, four sources close to the deal said.

08 Nov 2018

WRAPUP 1-Merck, Bristol-Myers profits rise on cancer drug sales

Oct 25 Merck & Co Inc and Bristol-Myers Squibb Co posted better-than-expected third quarter profit and raised their 2018 earnings forecasts on Thursday due to strong demand for their rival cancer immuno-oncology treatments.

25 Oct 2018

Bristol-Myers profit rises on better-than-expected cancer drug sales

NEW YORK, Oct 25 Bristol-Myers Squibb Co on Thursday posted better-than-expected third quarter profit and raised its full-year earnings forecast on strong demand for its cancer immunotherapy drugs.

25 Oct 2018

Roche scores win in slowing aggressive type of breast cancer

ZURICH/MUNICH An immunotherapy cocktail from Roche helped slow an aggressive type of breast cancer where new treatments have proven elusive, offering positive news for the Swiss drugmaker as it chases medicines produced by its rivals.

20 Oct 2018

UPDATE 1-Roche scores win in slowing aggressive type of breast cancer

* Trailing rivals, Roche seeking immunotherapy niches (Adds comments from lead study author, details on PD-L1 subgroup)

20 Oct 2018

CORRECTED-Roche's Tecentriq boosts survival in triple-negative breast cancer

ZURICH/MUNICH, Oct 20 An immunotherapy cocktail from Roche helped slow a type of breast cancer where new treatments have proven elusive, data released on Saturday showed, offering positive news for the Swiss drugmaker as it chases medicines produced by its rivals.

20 Oct 2018

Bristol-Myers' Opdivo fails to meet lung cancer study goal

Bristol-Myers Squibb Co said on Friday that its blockbuster cancer drug Opdivo failed to meet the main goal in a late-stage trial on patients with a type of lung cancer, whose condition had relapsed after chemotherapy.

12 Oct 2018

UPDATE 1-Bristol-Myers' Opdivo fails to meet lung cancer study goal

Oct 12 Bristol-Myers Squibb Co said on Friday that its blockbuster cancer drug Opdivo failed to meet the main goal in a late-stage trial on patients with a type of lung cancer, whose condition had relapsed after chemotherapy.

12 Oct 2018

Earnings vs. Estimates